Skip to content

UroGen Pharma URGN Long-Term Debt

Long-Term Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$42.15B-8.7%
Pfizer logo
PfizerPFE
$60.57B+5.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$37.53B-2.2%
Merck & Co. logo
Merck & Co.MRK
$49.1B+41.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$404.3M+36.5%
CG Oncology logo
CG OncologyCGON
$3M

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's long-term debt?
UroGen Pharma (URGN) reported long-term debt of $189.53M in Q1 2026.
How has UroGen Pharma's long-term debt changed year-over-year?
UroGen Pharma's long-term debt increased by 55.2% year-over-year, from $122.11M to $189.53M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.